key: cord-1017639-yldv5jxg authors: Bonnet, Benjamin; Chabrolles, Hélène; Archimbaud, Christine; Brebion, Amélie; Godignon, Maud; Dutheil, Frédéric; Lambert, Céline; Cosme, Justine; Mirand, Audrey; Ollier, Amandine; Pereira, Bruno; Regagnon, Christel; Vidal, Magali; Evrard, Bertrand; Henquell, Cécile title: Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination date: 2022-03-09 journal: J Infect DOI: 10.1016/j.jinf.2022.03.006 sha: b685dec0885dfcf37bd45b48ae596fc9311002ab doc_id: 1017639 cord_uid: yldv5jxg nan Dear Editor, Differences in effectiveness against severe disease were initially observed between COVID-19 vaccines during the period of predominance of the SARS-CoV-2 Alpha (B.1.1.7) variant, with mRNA vaccines (BNT162b2 and mRNA-1273) being more effective than the adenovirus-vectored ChAdOx1 vaccine [1] [2] [3] . After the emergence of the Delta (B.1.617.2) variant, a modest decrease in protection was noted after two doses of all vaccines. However, effectiveness against mild infection was substantially attenuated in comparison to Alpha variant, especially for the ChAdOx1 vaccine [4] [5] [6] . First data indicate that waning of protection against reinfection and symptomatic infection is faster for Omicron (B.1. 1.529) than for Delta infections [7] . We read with interest the article by Ferré et al, showing a drastic waning of antibody response 3 months after the second dose of BNT162b2 in healthcare workers (HCWs) associated with a loss of neutralization activities against variant strains [8] . Nevertheless, the assessment of T-cell responses, crucial for protection against SARS-CoV-2 infection and disease severity, has not been performed. To better understand differences of risk of COVID-19related outcomes, we need for supportive studies that evaluate the comparative immunogenicity conferred by different vaccines and vaccination strategies and their durability. 02 and p=0.03, respectively) . In contrast, no difference was found between the two groups for BNT162b2 or ChAdOx1 vaccines. We report the variable immunogenicity elicited by four different strategies of COVID-19 vaccines 3 months and 6 months after a primary course of vaccination. Our results confirm differences previously observed in side-to-side comparisons of vaccines early after vaccination and show that these differences last over time. Six months after vaccination, HCWs in both groups (uninfected and infected) vaccinated with mRNA-1273 had higher antibody titers and anti-spike T-cell response than those vaccinated with BNT162b2. However, the difference in immunogenicity according to previous infection was greater than the difference between the 2 mRNA vaccines. These results are consistent with those reported 3 to 10 weeks after vaccination [9, 10] . Previous studies indicated that a heterologous vaccination schedule with a first dose of ChAdOx1 followed by a second dose of mRNA vaccine provided higher antibody response one month after the boost than 2-dose ChAdOx1 [11] . Our results indicate that the greater effectiveness of ChAdOx1/BNT162b2 prime-boost vaccination was maintained for up to 6 months, and conferred humoral and cellular response similar to that of 2-dose BNT162b2. The clinical effectiveness of vaccines requires on-going (re) evaluation, particularly in the context of the emergence of variants of concern. Further long-term studies on the effect of booster vaccines (recommended since the late 2021) should help us to assess the dynamics of immunogenicity according to the vaccination regimens used over time and to validate the most effective vaccination strategies. The COVIDIM study is funded by the Clinical Research and Innovation Direction of the Clermont-Ferrand University hospital. Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the Ile-de-France VIII ethics committee of France and registered on ClinicalTrials.gov (NCT04896788). Written informed consent was obtained from all individuals included in this study. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases 2021 Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study SARS-CoV-2 variants of concern and variants under investigation Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial We thank all the healthcare workers enrolled in this study, and Jeffrey Watts for revision of the English manuscript. Authors state no conflict of interest Data AvailabilityThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.